Target intelligence / Profile preview

Nucleophosmin 1 pseudogene 52 (NPM1P52)

Target
NPM1P52
Molecular classification
Other (Processed pseudogene; long non-coding RNA family by genomic context[4])
01

Overview

Nucleophosmin 1 pseudogene 52 (NPM1P52) is a processed pseudogene related to the NPM1 gene, which encodes the nucleophosmin protein—a critical cellular chaperone and regulator of ribosome biogenesis, genomic stability, cell cycle, and apoptosis[1][3][5][7][8]. Unlike its functional parent gene, NPM1P52 does not express a protein product. However, some pseudogenes, including those of NPM1 family genes, may be transcribed and participate in regulatory networks through non-coding RNA functions, such as acting as microRNA decoys or contributing to the RNA interference pathway[2][4]. While pseudogenes can modulate disease-relevant biological processes, they are not typically direct therapeutic targets, and no drugs or biomarkers are assigned to NPM1P52 itself. There’s no evidence in current biomedical literature of NPM1P52 functioning as a classical receptor, enzyme, transporter, transcription factor, or a direct disease marker. If structured data is needed, these values adhere to the commonly accepted conventions in molecular target annotation. The entry is "incorrect" as a therapeutic target, as it does not correspond to a protein-coding receptor or enzyme or any established drug target class.

Other names
nucleophosmin (nucleolar phosphoprotein B23, numatrin) pseudogenenucleophosmin 1 (nucleolar phosphoprotein B23, numatrin) pseudogene 52NPM1P52
02

Biological functions

Regulation of parental gene expression (often via RNA interference or microRNA decoy activity[2])Potential modulation of mRNA stability through competition for *cis*- and *trans*-acting factors[2]Possible roles in gene dosage regulation and fine-tuning cellular response[2]
03

Disease associations

Other (pseudogenes may contribute to cancer through regulatory functions, but NPM1P52 is not directly implicated in disease in current literature[2])

Beyond the preview

Go deeper on Nucleophosmin 1 pseudogene 52 (NPM1P52).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nucleophosmin 1 pseudogene 52 (NPM1P52).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call